HANGZHOU, China, Sept. 13 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, today announced the Company has officially launched an English version of the Company's corporate website at http://en.aidapharma.com/. Aida Pharmaceutical's English corporate website includes detailed information about the Company, its management team and growing drug pipeline. Additionally, the website outlines Aida's market opportunity and value proposition in the Chinese pharmaceutical marketplace. Visitors to Aida's website will be able to sign up to receive news updates and a Company newsletter. Mr. Jin Biao, Aida Pharmaceuticals' Chairman, stated, "Aida Pharmaceuticals' English language website falls in line with the Company's efforts to openly and transparently communicate the corporate goals of Aida Pharmaceuticals, the Company's growing list of drug therapies and the market opportunity for our line of drug treatments in China. Aida's goal in launching an English version of our corporate website is to provide a resource for interested English users to learn about Aida and our advances in bringing revolutionary drug treatments to the Chinese public. En.aidapharma.com will be continuously updated with new information about the Company, our advances in the research and development of new drugs and our existing drug pipeline. We look forward to utilizing this resource to communicate with consumers and shareholders." About Aida Pharmaceuticals: Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China, Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China. Contact Information: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 Investor Relations: Equity Performance Group Gary Geraci (617) 723-2373 http://www.equityperformancegroup.com/ Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/. DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT: Gary Geraci of Equity Performance Group, +1-617-723-2373,

Copyright